4-Bromo-3,5-difluoroaniline | CAS:203302-95-8

We serve 4-Bromo-3,5-difluoroaniline CAS:203302-95-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Bromo-3,5-difluoroaniline

Chemical Name:4-Bromo-3,5-difluoroaniline
CAS.NO:203302-95-8
Synonyms:4-Bromo-3,5-difluoroaniline
4-bromo-3,5-difluoro-Benzenamine
4-bromo-3,5-difluoro-phenylamine
 
Physical and Chemical Properties:
Density 1.8±0.1 g/cm3
Boiling Point 223.7±35.0 °C at 760 mmHg
Melting Point 99-101°C
Molecular Formula C6H4BrF2N
Molecular Weight 208.003
Flash Point 89.1±25.9 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.570
 
Specification:
Appearance:White to light pink crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 4-Bromo-3,5-difluoroaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-3,5-difluoro-phenylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Bromo-3,5-difluoroaniline Use and application,4-Bromo-3,5-difluoroaniline technical grade,usp/ep/jp grade.


Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.Methyl 2-methyl-2-phenylpropanoate manufacturer It has also sought to win acceptance for TCM overseas, establishing 30 overseas TCM centers in countries along the “Belt and Road Initiative,” Xi’s global infrastructure and investment program.Phenylacetyl chloride supplier It has also sought to win acceptance for TCM overseas, establishing 30 overseas TCM centers in countries along the “Belt and Road Initiative,” Xi’s global infrastructure and investment program.(2-bromo-4-fluorophenyl)methanol vendor Here’s what Apple told CNN Business in a statement:Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders.